Sorry, looks like we don't have enough of this product.
Most "best ashwagandha" guides rank by aesthetics. None tell you what actually matters: how much active compound you're getting, whether it matches the clinical trials, and which UK brands meet the standard. This guide does the maths for you.
Most "best ashwagandha" guides in the UK rank products by aesthetics, packaging, or how they tasted on a tester's tongue. None of them tell you what actually matters: how much active compound (withanolides) you're getting, whether the dose matches the clinical trials, and whether the brand is hiding behind the label maths.
This guide does the maths for you.
It's a slightly longer read than most. That's because the supplement industry has become remarkably good at making one bottle of underpowered powder look identical to one bottle of clinical-grade extract — and the only way to tell them apart is to understand the science underneath.
By the end, you'll be able to look at any UK ashwagandha label and know in 60 seconds whether it's worth your £20.
If you only read this paragraph: the best ashwagandha in the UK in 2026 is KSM-66 root extract at 600mg per day, standardised to at least 5% withanolides, manufactured in Britain to GMP standards with an HPLC-tested withanolide spec stated clearly on the label. This is the dose used in the foundational stress and cortisol trial (Chandrasekhar 2012), validated again in the dose-response work (Salve 2019), and confirmed safe over a full year of daily use in the most recent long-term study (Salve 2025).
Most UK ashwagandha sold as "1,500mg high strength" actually delivers around 75mg of extract — well below clinical thresholds and unlikely to do anything measurable. The next 4,800 words explain why, how to spot the trick, and which UK brands meet the standard.
Withanolides are the active compound in ashwagandha. Everything ashwagandha is alleged to do — lower cortisol, improve sleep onset, reduce anxious mental noise, support recovery, modulate the HPA axis — flows from the withanolide content of the extract you're taking.
If a label doesn't tell you the withanolide percentage, you don't know what you're buying. This is the part most UK brands quietly hope you won't notice.
Withanolide content in commercially available UK ashwagandha ranges enormously:
This matters because two capsules labelled "500mg ashwagandha extract" can deliver radically different active compound. A 500mg capsule at 1.5% gives you 7.5mg of withanolides. A 500mg capsule at 5% gives you 25mg. That's a 233% difference in actual dose — from products that look identical on the shelf.
Use this to work out what you're actually getting from any ashwagandha product on the UK market:
Effective withanolide dose = Extract (mg) × Withanolide % ÷ 100
| Product label states | Extract per serving | Withanolide % | Actual withanolide dose | Verdict vs clinical trials |
|---|---|---|---|---|
| "600mg KSM-66, 5% withanolides" | 600mg | 5% | 30mg | Clinical-grade ✓ |
| "500mg Ashwagandha extract" (no spec) | 500mg | Unknown — assume worst case 1.5% | ~7.5mg | Sub-clinical |
| "3,000mg ashwagandha equivalent" (20:1 extract) | 150mg actual extract | Often 5% if disclosed | ~7.5mg | Marketing inflation |
| "1500mg high strength" | Often ~75mg actual extract (20:1) | Rarely disclosed | ~3–4mg estimated | Sub-clinical |
| "500mg, 10% withanolides" (HPLC tested) | 500mg | 10% | 50mg | Above clinical ✓ |
Clinical trials testing ashwagandha for stress, sleep and cortisol consistently use 25–30mg of withanolides per day (delivered via 600mg of KSM-66 at 5% standardisation). Anything substantially below that, you're guessing.
The withanolide percentage on a label can be measured two ways: HPLC (high-performance liquid chromatography) or gravimetric. HPLC is the gold standard — it identifies and quantifies specific withanolide compounds. Gravimetric testing measures total weight of a fraction extracted by solvent and tends to overstate withanolide content by roughly threefold compared to HPLC.
Brands aren't legally required to specify the testing method, so a "5% withanolides" claim from a gravimetric test might be ~1.6% by HPLC. Look for "HPLC-tested" or "HPLC-verified" on the label. This is a quiet quality signal that separates serious manufacturers from the rest.
"Ashwagandha" on a label can mean wildly different things. The major branded extracts available in the UK in 2026:
The most-studied ashwagandha extract in the world. Root only (no leaf), full-spectrum, standardised to 5% withanolides minimum (typically 2.5–5%). This is the extract used in roughly 95% of human clinical trials on ashwagandha for stress, sleep, cortisol, cognition and recovery. If the clinical evidence persuaded you to try ashwagandha, you should be taking KSM-66 — that's the form the trials validated.
Root and leaf extract, standardised to 10% withanolides (higher concentration, but with leaf material — which some consumers prefer to avoid). Smaller body of clinical evidence than KSM-66. Used in some UK brands but less common.
The newest entrant. Standardised to 35% glycowithanolides (a specific subset of withanolides). Marketed as more potent at lower doses (typically 60–120mg). Genuinely interesting biochemistry, but the human trial database is much smaller than KSM-66's. Reasonable choice for experienced users; not where most buyers should start.
Avoid unless you can verify the withanolide percentage by HPLC and the manufacturer's GMP credentials. The bulk-extract market for ashwagandha includes vast quality variation, including products containing significant leaf material that should not appear in root-only formulations.
The decision tree is simple. If you want the supplement that matches the clinical research, take KSM-66 root extract. The other extracts have legitimate uses but are not what most published trials evaluated. Elysium's Ashwagandha uses KSM-66 at the clinical 600mg dose with 5% withanolides specified on the label.
The body of human research on ashwagandha is now substantial enough to make confident dose recommendations for specific outcomes. Here are the trials that matter most for UK buyers in 2026, with the actual doses each one used.
Chandrasekhar 2012 — the foundational stress trial. 64 adults with chronic stress, double-blind, placebo-controlled, 60 days. Treatment: 300mg of KSM-66 ashwagandha twice daily (600mg total). Result: serum cortisol reduced by 27.9% versus placebo, with significant reductions across the Perceived Stress Scale (p<0.0001). This is the trial that put ashwagandha on the modern clinical map.
Salve 2019 — the dose-response trial. 60 adults under stress, randomised to placebo, 250mg/day, or 600mg/day of KSM-66. Result: both doses lowered cortisol significantly, but 600mg outperformed 250mg on every measured stress and sleep marker. This is the trial that ended the "is 250mg enough?" debate.
Salve 2025 — the 12-month safety trial. The most recent published data (Wiley, October 2025). Healthy adults taking 600mg KSM-66 daily for a full year. Result: no adverse effects on liver function, kidney function, thyroid function, or lipid profile. Confirmed sustained mild reduction in serum cortisol over 12 months. This is the longest-duration ashwagandha safety trial currently published, and zero UK consumer brands have caught up to citing it.
Langade 2019 — randomised, double-blind, placebo-controlled trial in 60 adults with insomnia and anxiety. Treatment: 600mg of KSM-66 daily for 10 weeks. Result: sleep onset latency reduced significantly, sleep efficiency improved, and insomnia severity scores fell substantially versus placebo.
Choudhary 2017 — 50 adults with mild cognitive impairment took 600mg of KSM-66 daily for 8 weeks. Result: significant improvements in immediate memory, general memory, executive function, sustained attention, and information processing speed compared to placebo. The cognitive benefits at 600mg KSM-66 are now well-established.
Wankhede 2015 — 57 men randomised to 600mg KSM-66 daily or placebo while undertaking resistance training over 8 weeks. Result: significantly greater gains in muscle strength, muscle size, and recovery markers in the ashwagandha group, alongside meaningful reductions in exercise-induced muscle damage.
| Goal | Clinically validated dose | Time to onset | Key trial |
|---|---|---|---|
| Stress / cortisol | 600mg KSM-66 daily | 4–8 weeks | Chandrasekhar 2012, Salve 2019 |
| Sleep onset / quality | 600mg KSM-66 daily | 6–10 weeks | Langade 2019 |
| Cognitive performance | 600mg KSM-66 daily | 4–8 weeks | Choudhary 2017 |
| Strength / recovery | 600mg KSM-66 daily | 6–8 weeks | Wankhede 2015 |
| Long-term safety | 600mg KSM-66 daily for 12 months | Confirmed safe | Salve 2025 |
The pattern is striking. Across stress, sleep, cognition and recovery, the clinically validated dose converges on 600mg of KSM-66 daily. There is no compelling published evidence that "more is better" once you cross this threshold. There is significant evidence that less is significantly less effective. Our complete ashwagandha dosage guide goes deeper on the dose-response data.
Walk into any UK pharmacy or scroll Amazon and you'll see ashwagandha labels claiming "1500mg high strength" or "3000mg maximum potency" or "10,000mg whole-herb equivalent." These claims are technically true and commercially misleading.
Here's how the trick works.
A "20:1 extract" means 20kg of raw ashwagandha was theoretically used to produce 1kg of extract. So a label saying "1500mg ashwagandha (from 20:1 extract)" actually delivers 75mg of extract powder. If that 75mg is at 5% withanolides, you're getting 3.75mg of active compound — roughly 8x less than the clinical 30mg dose used in trials.
The 20:1 ratio itself is unverifiable. There is no industry standard test confirming whether an extract is genuinely 20:1, 10:1, or 5:1. Manufacturers can claim almost any ratio without consequence.
"3000mg whole-herb equivalent" sounds impressive. It means: if you took the small amount of extract in this capsule and reverse-calculated how much raw root would have been needed to produce it, that figure equals 3000mg. It tells you nothing about the actual extract you're consuming — only about a hypothetical untransformed plant.
Many UK brands add a few milligrams of black pepper extract (BioPerine) to ashwagandha and claim "enhanced absorption." Here's the issue: every clinical trial that established ashwagandha's effects at 600mg used the extract without black pepper. The doses the research validated are the doses without absorption enhancement. Adding black pepper isn't necessarily bad, but it's not the reason the supplement works, and it doesn't let you reduce the underlying dose.
Most UK ashwagandha gummies deliver 100–250mg of extract per serving. They taste pleasant. They will not deliver clinical effects. If you're choosing between a gummy at 200mg and a capsule at 600mg KSM-66 with named withanolide percentage, the capsule wins by orders of magnitude.
Ashwagandha has emerged as one of the most discussed adaptogens for women in their 40s and 50s, particularly during perimenopause. The reason is mechanical: as oestrogen declines, the HPA axis becomes more reactive, cortisol rhythms destabilise, and the "wired but exhausted" pattern (high evening cortisol, fragmented sleep, racing mind in bed) becomes increasingly common. This is exactly the cortisol curve ashwagandha appears to modulate.
Salve 2019 included women in its sample. Chandrasekhar 2012 had mixed-gender participants, and the cortisol reduction was significant across both sexes. Salve 2025's 12-month safety trial confirmed sustained benefit and tolerability over a year of daily use in adult women. The clinical evidence base for women is increasingly robust.
For perimenopausal women, the typical reported pattern is:
One nuance worth flagging: ashwagandha can mildly stimulate thyroid function. Women with autoimmune thyroid conditions (Hashimoto's, hyperthyroidism) should consult a clinician before starting. For women without thyroid pathology, this effect is generally not problematic and may be mildly beneficial.
For sleep-led perimenopausal symptoms, the combination of ashwagandha with magnesium glycinate at bedtime is well-supported. We've covered the underlying biology in magnesium and cortisol and the protocol specifics in our best magnesium for sleep guide.
The male buyer market for ashwagandha is dominated by claims about testosterone. The published evidence is more nuanced than most marketing suggests, but it does exist.
Lopresti 2019 — 57 overweight men aged 40–70 took 600mg of ashwagandha daily for 8 weeks. Result: significant increase in serum testosterone (14.7%), reduction in fatigue, and improvement in vigour. Modest but real.
Wankhede 2015 — 57 men undertaking resistance training, 600mg KSM-66 daily for 8 weeks. Result: significantly greater gains in strength, muscle size, and reduced muscle damage versus placebo. Testosterone increased modestly in the ashwagandha group.
The honest summary: ashwagandha at 600mg KSM-66 daily appears to produce modest testosterone increases (10–15%) in middle-aged men, with somewhat larger effects in those with low baseline levels or under significant training stress. It is not a testosterone replacement. It is a meaningful complement to good sleep, training, and nutrition for men whose stress and recovery are suppressing baseline hormone function.
For men using ashwagandha primarily for training recovery, pairing with Lion's Mane for cognitive performance is well-evidenced. The combination is covered in detail in our ashwagandha and Lion's Mane combination guide, and the cognitive timeline of Lion's Mane is unpacked in our how long does Lion's Mane take to work article.
Use this in 60 seconds the next time you're staring at an ashwagandha bottle in a shop or on a product page.
Names the branded extract (KSM-66, Sensoril or Shoden), states the dose in milligrams, specifies the withanolide percentage with HPLC-tested confirmation, declares UK GMP manufacturing, lists clean ingredients with no proprietary blends.
Example: "KSM-66® Ashwagandha root extract 600mg, standardised to 5% withanolides (HPLC tested). Manufactured in the UK to GMP standards."
States the extract dose in mg with a withanolide percentage, but doesn't specify HPLC testing or branded extract origin. May still be a quality product but you're trusting the manufacturer's quality control without independent verification.
States only "ashwagandha extract 500mg" with no withanolide percentage, no extract type, no testing method. You don't know what you're buying. Could range from genuinely effective to inert plant material.
Headlines large numbers ("3000mg high strength," "10,000mg whole-herb equivalent") without disclosing actual extract content, ratio, or withanolide percentage. The marketing is doing all the work; the label is not telling you what's inside.
Powder, no standardisation, no testing, no manufacturer transparency. Bulk material with unknown contamination risk and unknown withanolide content.
Six questions to run on any UK ashwagandha label:
Six yeses = Tier 1. Five = Tier 2. Three or four = Tier 3. Fewer = Tier 4 or 5. This single audit will eliminate roughly 80% of the UK ashwagandha market from your shortlist.
After applying the label audit and dose calculator above, the UK shortlist narrows considerably. Here is an honest, label-grounded comparison of brands available to UK buyers in 2026.
| Brand | Extract type | Daily dose | Withanolide % | Clinical match | UK GMP | Tier |
|---|---|---|---|---|---|---|
| Elysium Ashwagandha | KSM-66 | 600mg | 5% (stated) | Matches Chandrasekhar 2012, Salve 2019, Salve 2025 | Yes | Tier 1 |
| Wild Nutrition Food-Grown Ashwagandha KSM-66 Plus | KSM-66 | 600mg | Stated | Matches | Yes | Tier 1 |
| Time Health Ashwagandha | Generic standardised extract | 500mg (1 cap) | 10% (HPLC stated) | Above clinical (no KSM-66 trial match) | Yes | Tier 1–2 |
| Together Health Ashwagandha | KSM-66 | 500mg | Stated | Slightly below clinical 600mg | Yes | Tier 2 |
| Solgar Ashwagandha Root Extract | Standardised extract | ~300mg | 1.5% | Sub-clinical | Yes | Tier 3 |
| Generic high-street "1500mg high strength" | Unspecified extract ratio | Often ~75mg actual extract | Rarely disclosed | Sub-clinical | Variable | Tier 4 |
Elysium Ashwagandha meets the full clinical specification: KSM-66 root extract at 600mg per day, 5% withanolides, UK-made to GMP standards, transparent label with no proprietary blends. This is the dose used in every major stress, cortisol, sleep and cognition trial cited above. Currently £24.99 for a 60-day supply — roughly £0.42 per clinically validated daily dose.
If you're using ashwagandha primarily to manage stress and improve cognitive performance simultaneously, the Stress & Focus Stack pairs KSM-66 ashwagandha with Lion's Mane mushroom extract — combining the cortisol-modulating evidence of ashwagandha (Chandrasekhar 2012) with the neurotrophic data on Lion's Mane (Mori 2009). This combination is also covered in detail in our Ashwagandha and Lion's Mane combination guide.
If your primary issue is sleep disruption driven by stress, pairing ashwagandha with magnesium glycinate is well-evidenced. The combination is detailed in our magnesium and ashwagandha guide, and the underlying cortisol-magnesium relationship is unpacked further in our magnesium and cortisol article.
"High strength 1500mg ashwagandha" with no extract ratio, no withanolide percentage, and no manufacturer transparency. Pricing typically £8–£12 for 60 capsules. Maths suggest sub-clinical doses delivering 3–5mg of active withanolides per day — well below the 25–30mg used in published trials.
Generic ashwagandha at £6 for 90 capsules is almost mathematically incapable of delivering clinical doses. The raw cost of properly extracted KSM-66 sets a floor on what any honest brand can charge. Below £15–£20 for a 60-day supply at 600mg per day, something is being cut.
"High strength" is a marketing phrase with no legal definition. The only way to verify strength is the withanolide milligram total per daily serving. Run the calculator above on any product before deciding.
Organic certification confirms farming standards. It does not confirm withanolide content, extraction quality, or clinical match. An organic ashwagandha at 1.5% withanolides is still sub-clinical for stress and cortisol effects, organic certification notwithstanding.
The dose isn't 1500mg. The dose is 25–30mg of withanolides. 1500mg of a 1.5% extract is about 22mg of withanolides — close to clinical, but inconsistent. 600mg of 5% KSM-66 is exactly 30mg of withanolides — what the trials measured. The branded extract gets you there with smaller, more reliable doses.
Most ashwagandha trials show effects beginning around 4 weeks and consolidating between weeks 6 and 10. The Chandrasekhar 2012 trial measured cortisol reduction at 60 days. The Langade 2019 sleep trial ran 10 weeks. If you're 14 days in and feel nothing, you're not at the timepoint where most users notice the change. Give it eight full weeks before drawing conclusions.
Ashwagandha is sold in the UK as a food supplement, regulated by the Food Standards Agency (FSA). It is not classified as a medicine and therefore cannot make medical claims (e.g. "treats anxiety," "cures insomnia"). Reputable UK brands describe ashwagandha's effects in non-medical language ("supports relaxation," "helps the body adapt to stress"), which is why honest brand language can sometimes feel intentionally restrained.
Ashwagandha is not currently classified as a Novel Food in the UK. It is widely permitted for sale by retailers and direct-to-consumer brands. However, manufacturers selling ashwagandha must hold proper GMP (Good Manufacturing Practice) certification. UK-made GMP products are independently audited; products manufactured offshore and shipped to UK consumers may not meet the same standards even if labelled identically.
Buying direct from a UK-based brand with verifiable GMP credentials gives you a meaningful quality guarantee that Amazon reseller listings do not. The ashwagandha you receive on Amazon may not always come from the manufacturer the listing implies; supply chain provenance matters for botanical extracts more than for synthetic vitamins.
If you start ashwagandha today, here's a simple framework to track whether it's working. Score each marker out of 10 every Sunday for eight weeks. Track on your phone notes app — no spreadsheet needed.
| Marker | What to score | Expected change by week 8 |
|---|---|---|
| Stress baseline | How "wound up" do you feel on average this week? (10 = calm, 1 = wired) | Baseline lifts by 1.5–3 points in most users |
| Sleep onset time | How long does it take to fall asleep? (Estimate in minutes) | Reduction of 10–25 minutes typical (Langade 2019) |
| Sleep quality | How rested do you feel waking up? (10 = fully restored, 1 = depleted) | Quality score lifts by 1–2 points |
| Morning energy | Energy and clarity in the first hour after waking (10 = sharp, 1 = foggy) | Most users report clearer mornings by week 6 |
| Mental noise | Background "racing mind" intensity (10 = quiet, 1 = constant) | Substantial drop in mental noise is the most commonly reported effect |
If three or more of these markers improve by week 8, ashwagandha is doing something measurable for you. If none have moved, see the troubleshooting section below before assuming it doesn't work.
Most "ashwagandha doesn't work for me" reports are explainable by one of five issues. Run through this list before giving up.
Run the dose calculator on whatever product you're using. If you're getting under 25mg of withanolides per day, you're under-dosed. The fix is not "take more of the underdosed product" — it's switch to a properly specified KSM-66 600mg formulation.
Ashwagandha works through HPA-axis adaptation, which is a slow process. Missing 2–3 days a week meaningfully delays the timeline. Daily dosing is non-negotiable for the first eight weeks.
Severe chronic stress (clinical-level burnout, ongoing sleep deprivation under five hours, untreated anxiety disorders) can outpace ashwagandha's effects. The supplement modulates cortisol output but cannot fully compensate for sustained, severe stressors. Address the inputs first; supplements support but do not replace fundamental recovery.
Six weeks is the rough median for noticing effects. Eight weeks is the median for consolidating them. Cortisol reduction in Chandrasekhar 2012 was measured at 60 days; sleep onset improvement in Langade 2019 was measured at 10 weeks. Two weeks is too early to draw any conclusions.
The Salve 2025 12-month safety trial confirms 600mg KSM-66 is safe long-term. Some users with very high stress baselines find 1200mg (600mg twice daily) more effective — typically by week 6 if 600mg hasn't moved the needle. There is no published evidence supporting doses above 1200mg KSM-66 for routine use; safety data above this threshold is limited.
The best ashwagandha in the UK in 2026 is KSM-66 root extract at 600mg per day, standardised to 5% withanolides, manufactured in Britain to GMP standards. This matches the dose used in the foundational Chandrasekhar 2012 cortisol trial and the more recent Salve 2019 dose-response study.
KSM-66 is the most clinically researched ashwagandha extract and the form used in roughly 95% of human trials. For stress, sleep, cortisol, cognition and recovery research, KSM-66 has the strongest evidence base of any ashwagandha extract currently available.
The clinically validated dose is 600mg of KSM-66 ashwagandha root extract daily, standardised to at least 5% withanolides. This delivers approximately 30mg of withanolides per day — the dose used in the published trials demonstrating cortisol reduction, sleep improvement, and cognitive benefit.
Most users notice effects between weeks 4 and 8 of daily use. The foundational cortisol trial measured significant reductions at 60 days. Sleep improvements typically appear by week 6–10. Cognitive effects emerge between weeks 4 and 8. If you feel nothing at two weeks, that is normal and expected.
The most recent safety data (Salve 2025) confirmed daily 600mg KSM-66 use over a full year produced no adverse effects on liver, kidney, thyroid, or lipid markers. Long-term daily use at clinical doses appears safe in healthy adults, though anyone on prescription medication should consult a clinician before extended use.
KSM-66 is a root-only extract standardised to 5% withanolides. Sensoril is a root and leaf extract standardised to 10% withanolides. KSM-66 has a much larger body of human clinical evidence; Sensoril is less studied in consumer outcomes. For clinical-match dosing, KSM-66 is the more evidence-supported choice.
Both work. Morning dosing is associated with more pronounced energy and cognitive effects through the day. Evening dosing pairs well with sleep-onset benefits. If you're stacking with magnesium glycinate for sleep, evening makes sense; if cognitive performance is the priority, morning dosing is preferred. The clinical trials used twice-daily dosing (300mg morning, 300mg evening) — the most reliable approach if convenience allows.
It depends entirely on what's actually in the 1500mg. Most "1500mg high strength" UK products are 20:1 extracts containing roughly 75mg of actual extract — substantially less than clinical doses. Genuine 1500mg of KSM-66 extract would be 2.5x the clinical dose; safety data above 1200mg/day is limited. The relevant question is not the milligram total, but the milligrams of withanolides delivered.
The clinical evidence for ashwagandha at 600mg KSM-66 daily is substantial. Multiple randomised, double-blind, placebo-controlled trials have demonstrated significant effects on cortisol, perceived stress, sleep onset, sleep quality, cognitive function, and physical recovery. Effects vary by individual; the evidence supports meaningful average effects in healthy adults using clinical-grade extracts at clinical doses.
Ashwagandha is generally well-tolerated. Reported side effects in clinical trials (Chandrasekhar 2012, Salve 2025) are typically mild — occasional gastrointestinal discomfort, drowsiness, or headache, occurring at similar rates to placebo. Pregnant or breastfeeding women should not use ashwagandha. People with autoimmune thyroid conditions or those taking immunosuppressants should consult a clinician before use.
Yes. Ashwagandha is legally sold in the UK as a food supplement, regulated by the Food Standards Agency. It is not classified as a Novel Food and does not require special authorisation. Reputable brands manufacture to GMP standards under UK regulations.
Ashwagandha pairs well with magnesium glycinate (for sleep and stress), Lion's Mane (for cognitive performance and stress), and standard multivitamins. It should be used with caution alongside sedative medications, thyroid medications, and immunosuppressants. The combination with Lion's Mane is covered in detail in our dedicated combination guide.
The best ashwagandha in the UK in 2026 is the one that matches the clinical research: KSM-66 root extract, 600mg daily, 5% withanolides, HPLC-tested, UK-made to GMP standards, with a transparent label that states all of the above plainly.
Most of the UK ashwagandha market does not meet this standard. The "1500mg high strength" products dominating Amazon and high-street pharmacies are mathematically unable to deliver clinical doses. The premium brands that do meet the standard are honest about what's in the bottle, because they have nothing to hide.
If you've read this far, you now have everything you need to choose well. The dose calculator. The label hierarchy. The clinical doses. The brand comparison. The eight-week tracker.
The supplement industry would prefer you didn't have any of this. We think you should.
Ready to start? Elysium's KSM-66 Ashwagandha meets every Tier 1 criterion in this guide. Or explore our bundles if you're stacking ashwagandha with magnesium glycinate, Lion's Mane, or both.
This guide is for educational purposes and does not constitute medical advice. Please consult a qualified healthcare professional before starting any new supplement, particularly if you are pregnant, breastfeeding, taking prescription medication, or managing a medical condition.
Lion's Mane and Ashwagandha. Together, by design.
SHOP THE STRESS & FOCUS STACK
